Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 11:15 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 81 matching trials from the live ClinicalTrials.gov search.
Conditions
Post Traumatic Stress Disorder, Depression - Major Depressive Disorder
Interventions
Psilocybin + MBCT therapy, Active Comparator: Psilocybin with Support Only
Combination Product
Lead sponsor
Anthony P King
Other
Eligibility
21 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Major Depressive Disorder
Interventions
Psilocybin
Drug
Lead sponsor
Maryland Oncology Hematology, PA
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Rockville, Maryland
Conditions
Post-Traumatic Headache
Interventions
Placebo oral capsule, Low Dose Psilocybin, High Dose Psilocybin
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
West Haven, Connecticut
Conditions
Major Depressive Disorder
Interventions
No intervention will be administered as part of this study.
Other
Lead sponsor
Usona Institute
Other
Eligibility
21 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Lauderhill, Florida
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Effects of Psilocybin on Electrophysiology and the Dynamic Content of Thought

NCT05301608
Conditions
Healthy
Interventions
Psilocybin, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Active, not recruiting Phase 2 Interventional

Psilocybin in Cancer Pain Study

NCT06001749
Conditions
Opioid-Related Disorders, Pain Management, Pain Management and Care, Advanced Cancer, Advanced Cancers
Interventions
Psilocybin
Drug
Lead sponsor
Yvan Beaussant, MD, MSci
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Pancreas Cancer, Biliary Tract Cancer, Psychological Distress, Gastrointestinal Cancer
Interventions
Psilocybin
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 85 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Omaha, Nebraska
Conditions
Anhedonia, Emotional Blunting
Interventions
Psilocybin, Placebo
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 65 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
New York, New York
Conditions
Parkinson Disease, Depression
Interventions
Psilocybin, Pimavanserin
Drug
Lead sponsor
Joshua Woolley, MD, PhD
Other
Eligibility
40 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
San Francisco, California
Conditions
Anxiety, Depression, Hematopoietic and Lymphatic System Neoplasm, Metastatic Malignant Solid Neoplasm
Interventions
Psychotherapy, Psilocybin, Survey Administration
Behavioral · Drug · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 85 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Phase I
Interventions
Psilocybin (Usona Institute), Inactive Placebo (Usona Institute)
Drug
Lead sponsor
Brown University
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Providence, Rhode Island
Recruiting Phase 1 Interventional Accepts healthy volunteers

Investigation of Psychedelic Effects in Psychoactive Substances

NCT06772753
Conditions
Psychedelic Effects in Healthy Volunteers
Interventions
Placebo, Psilocybin, Ketamine, Dextromethorphan (DXM), Dimethyltryptamine (DMT), Methylenedioxymethamphetamine (MDMA), Tetrahydrocannabinol (THC)
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
25 Years to 55 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Withdrawn Early Phase 1 Interventional Accepts healthy volunteers

Exploratory Study of Low Dose Psilocybin

NCT05227742
Conditions
Demoralization
Interventions
Psilocybin, Placebo
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
25 Years to 65 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Birmingham, Alabama
Completed Early Phase 1 Interventional Accepts healthy volunteers

Precision Functional Brain Mapping in Psilocybin

NCT04501653
Conditions
Psilocybin
Interventions
Psilocybin, Methylphenidate
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 40 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
St Louis, Missouri
Not listed Phase 1 Interventional Accepts healthy volunteers

Comparing the Effects of Psilocin and Psilocybin in Healthy Adults

NCT05317689
Conditions
Healthy
Interventions
Psilocin, Psilocybin, Sublingual Psilocin
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
25 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
San Francisco, California
Conditions
Alzheimer's Disease
Interventions
Psilocybin, Cognitive Training
Drug · Other
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
65 Years to 120 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Bipolar II Disorder
Interventions
Psilocybin therapy
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 70 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
San Francisco, California
Conditions
Spinal Cord Injury, Depression - Major Depressive Disorder, Veteran
Interventions
Psilocybin (Usona Institute)
Drug
Lead sponsor
James J. Peters Veterans Affairs Medical Center
Federal
Eligibility
22 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
The Bronx, New York
Conditions
Fibromyalgia, Primary
Interventions
Psilocybin, Dextromethorphan
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
25 Years to 65 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Birmingham, Alabama
Conditions
Psilocybin, Neuropathy
Interventions
Psilocybin (drug), Standard of Care (SOC)
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Houston, Texas
Conditions
Hospice, Psilocybin, Demoralization, Terminal Illness, Cancer-related Problem/Condition, Psychotherapy, Terminal Cancer, Cancer Terminal
Interventions
Psilocybin, Psychotherapy
Drug · Behavioral
Lead sponsor
Yvan Beaussant, MD, MSci
Other
Eligibility
21 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Danvers, Massachusetts
Conditions
Major Depressive Disorder, Anhedonia, Treatment Resistant Depression
Interventions
Psilocybin 25mg, Placebo (active placebo)
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
21 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Binge Eating Disorder
Interventions
TRYP-0082, Psychotherapy
Drug · Behavioral
Lead sponsor
TRYP Therapeutics
Industry
Eligibility
18 Years to 64 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Gainesville, Florida
Conditions
Distress, Depression, Grief
Interventions
Psilocybin, Modified brief Supportive Expressive Group Therapy
Drug · Behavioral
Lead sponsor
Joshua Woolley
Other
Eligibility
50 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
San Francisco, California